Predictive Oncology (NASDAQ: POAI), a leader in artificial-intelligence (“AI”)-driven drug discovery and biologics, is reporting on a study that demonstrates the long-term stability and viability of the more than 150,000 cryopreserved patient tumor samples available within its proprietary biobank. According to the report, the study validates highly reproducible drug response data as well as enabling and supporting the AI platform to model and predict patient outcomes on historical samples. The company has released a new white paper that discusses this study, and the importance of tumor sample viability, in greater detail.
“We are extremely pleased with the results of this study, which demonstrates that even after an extended period of time — some as long as 16 years — the samples cryopreserved in our biobank remain viable and able to deliver the same drug response data as when originally tested,” said Predictive Oncology SVP of Translational Medicine and Drug Discovery Dr. Arlette Uihlein in the press release. “This not only validates the utility of our biobank, but also the strength and reliability of the drug response data that we compiled over those many years. We are uniquely positioned to enable drug developers to query patient responses to their drug candidates, accounting for real-world patient heterogeneity, and to validate targets and biomarkers long before human clinical trials commence.”
To view the white paper, visit https://ibn.fm/8Xq8v
To view the full press release, visit https://ibn.fm/PDz74
About Predictive Oncology Inc.
Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence (“AI”) and machine learning (“ML”) to expedite early biomarker and drug discovery and enable drug development for the benefit of cancer patients worldwide. The company’s proprietary AI/ML platform has been scientifically validated to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. With the company’s vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry’s broadest AI-based, drug-discovery solutions, further complemented by its wholly owned Clinical Laboratory Improvement Amendments (“CLIA”) lab and GMP facilities. For more information about the company, please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About TinyGems
TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.TinyGems.com
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer
TinyGems
Los Angeles, CA
www.TinyGems.com
310.299.1717 Office
Editor@TinyGems.com
TinyGems is powered by IBN
